The 2020 EURETINA Clinical Research Award (the “Award”) is an initiative sponsored by EURETINA to support and encourage independent clinical research in the field of retinal medicine.
Clinical research, as proposed by clinician or non-clinician researchers, may conduct several types of clinical research, such as observational research studies, register studies (patient or disease registry), natural history / epidemiological studies, phase IV studies (post-authorisation safety studies, “PASS”), genomic research studies, pharmacovigilance studies, retrospective case-control studies, systematic reviews, meta-analyses and several other types of clinical studies.
The Clinical Research Call for FY2020 aims to fund up to six (6) research projects. The maximum amount that might be awarded to a successful applicant is no more than €300K, always subject to the quality of the research proposal and the benefits for patients.
The competition is open to all clinicians and researchers, with EURETINA membership, holding a full time clinical/research post at an EU-based clinical or academic centre (H2020 associated countries*).
*(Iceland, Norway, Albania, Bosnia and Herzegovina, the former Yugoslav Republic of Macedonia, Montenegro, Serbia, Turkey, Israel, Moldova, Switzerland, Faroe Islands, Ukraine, Tunisia, Georgia, Armenia)
Funding may be available over 2 years (maximum duration) for the right project with suitable infrastructure and experience.
The competition is open to all applicants from the European Union (EU) and several additional countries (designated by H2020 associated countries) who have been members of EURETINA for longer than 12 months. Applicants must hold a full time clinical/research post at a EU-based clinical or academic centre. EURETINA looks forward to receiving your entries for which the ultimate beneficiary of your efforts will be the ophthalmic patient and the clinical ophthalmology community.
What are we looking for:
The EURETINA Clinical Research Award are as much to do with good clinical science as they are to do with the capability to execute a solid research project creating near-term clinical impact. Any compelling scientific or medical rationale will need to be matched by an equally compelling infrastructure and research expertise that has been demonstrated to deliver on similar initiatives in the past. The combination of clinical science and clinical research expertise is the key to convincing the EURETINA Research Committee and your peers of a credible and attractive clinical research programme.
All eligible Expressions-of-Interest will be evaluated by the EURETINA Research Call Review Panel from which short listed entries will be invited to make a full proposal.
Any queries prior to submission of an Expression-of-Interest application should be directed to Dr. Gearóid Tuohy, Director, Clinical Trials, EURETINA Clinical Research Award (firstname.lastname@example.org).
2020 EURETINA Clinical Research Award – Research Call Review Panel
22 March 2019 (18.00hrs, GMT): Deadline for receipt of Expressions-of-Interest
Early July 2019: Invitation to short-listed applicants to submit full proposals.
12 August 2019: Receipt of full proposals from shortlisted applicants
EURETINA 2019 Congress, Paris, 5-8 Sept 2019 Announcement of 2019 Clinical Research Award
Applications open in late November 2019.
Terms and Conditions
(a) I/We hold a full-time or affiliated post with an established EU-based (and H2020 associated countries) clinical or research institute, as named on my Expression-of-Interest submission.
(b) I/We have demonstrable prior experience in the conduct of non-interventional clinical research in the field of retinal medicine and hold demonstrable GCP experience.
(c) I/We am/are familiar and experienced with the administrative, insurance and regulatory requirements for the conduct of EU-based clinical research studies.
(d) As Principal Applicant, I am a member of EURETINA for more than 12 months and my EURETINA membership number is included on my Expression-of-Interest submission.
(e) Expressions-of-Interest will be evaluated by the EURETINA Research Call Review panel who will generate a short-list of applicants to be invited to make a full comprehensive research proposal to EURETINA. All decisions on Expressions-of-Interest and short-listed proposals made by EURETINA shall be final and no correspondence will be entered into in relation to decisions made.
(e) Officers on the EURETINA Executive, Board and Trustees shall not be eligible to apply for the Expressions-of-Interest.
You must agree to these Terms and Conditions before you can submit your Application